Quintiles Transitional Holdings (Q) Shares are Down -1.77%

Quintiles Transitional Holdings (Q) has risen sharply, recording gains of 6.6% in the past 4 weeks. However, the stock has corrected -1.77% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 5.51% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.1% and the 50-Day Moving Average is 9%. Quintiles Transitional Holdings (NYSE:Q): On Fridays trading session , Opening price of the stock was $76.64 with an intraday high of $76.81. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $76.08. However, the stock managed to close at $76.4, a loss of 0.46% for the day. On the previous day, the stock had closed at $76.75. The total traded volume of the day was 803,775 shares.


The company Insiders own 10.9% of Quintiles Transitional Holdings shares according to the proxy statements. Institutional Investors own 86.12% of Quintiles Transitional Holdings shares. During last six month period, the net percent change held by insiders has seen a change of 32.18%. Also, Equity analysts at the Brokerage firm Citigroup maintains its rating on Quintiles Transitional Holdings (NYSE:Q). The rating major has initiated the coverage with neutral rating on the shares. The Analysts at Citigroup raises the price target from $72 per share to $75 per share. The rating by the firm was issued on July 28, 2016.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.